Cargando…

Reply: Potential Use of Radiolabeled Antibodies for Imaging and Treatment of COVID-19

Detalles Bibliográficos
Autores principales:	Pillarsetty, Nagavarakishore, Carter, Lukas M., Lewis, Jason S., Reiner, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society of Nuclear Medicine 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882887/ https://www.ncbi.nlm.nih.gov/pubmed/33893187 http://dx.doi.org/10.2967/jnumed.121.261950

Ejemplares similares

Oncology-Inspired Treatment Options for COVID-19
por: Pillarsetty, Nagavarakishore, et al.
Publicado: (2020)

Potential Use of Radiolabeled Antibodies for Imaging and Treatment of COVID-19
por: Dadachova, Ekaterina
Publicado: (2021)

Rapid detection of SARS-CoV-2 using a radiolabeled antibody
por: Pirovano, Giacomo, et al.
Publicado: (2021)

Building Blocks for the Construction of Bioorthogonally Reactive Peptides via Solid-Phase Peptide Synthesis
por: Zeglis, Brian M, et al.
Publicado: (2014)

The Unique Pharmacometrics of Small Molecule Therapeutic Drug Tracer Imaging for Clinical Oncology
por: Dunphy, Mark P. S., et al.
Publicado: (2020)

Pharmacokinetic Imaging with Radiolabeled Molecularly Targeted Anticancer Drugs
por: Bauer, Martin, et al.
Publicado: (2020)

Radioiodinated PARP1 tracers for glioblastoma imaging
por: Salinas, Beatriz, et al.
Publicado: (2015)

Reply to “Novaferon, treatment in COVID-19 patients”
por: Zheng, Fang, et al.
Publicado: (2021)

In Reply—How Safe Is COVID-19 Convalescent Plasma?
por: Joyner, Michael J., et al.
Publicado: (2021)

Radiolabeled Antibodies for Cancer Imaging and Therapy
por: Parakh, Sagun, et al.
Publicado: (2022)

‘Treatment of COVID-19 with convalescent plasma’ – Author’s reply
por: Wooding, Denise J., et al.
Publicado: (2021)

“ISTH guidelines for antithrombotic treatment in COVID‐19”: Reply
por: Schulman, Sam, et al.
Publicado: (2022)

Treatment of acute radiation cystitis: reply by the authors
por: Hazewinkel, Menke, et al.
Publicado: (2011)

In Reply: Hormones and COVID-19
por: Park, Myung S., et al.
Publicado: (2023)

Reply to: Hemichorea Associated with CASPR2 Antibody
por: Ramdhani, Ritesh A., et al.
Publicado: (2014)

Authors’ reply
por: Bajracharya, A, et al.
Publicado: (2010)

In Reply — Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients
por: Joyner, Michael. J., et al.
Publicado: (2020)

Reply to “Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19”
por: Khan, Md. Saiful Islam, et al.
Publicado: (2021)

Reply to “The outbreak of COVID-19: An overview”
por: Wu, Yi-Chi, et al.
Publicado: (2020)

Reply: CPET for Long COVID-19
por: Mancini, Donna M., et al.
Publicado: (2022)

Reply to the syndemic of “COVID-19 and tuberculosis”
por: Patil, Rajashri A., et al.
Publicado: (2023)

Reply to “Antiviral and anti-inflammatory properties of ivermectinand its potential use in Covid-19”()
por: Accinelli(), Roberto Alfonso, et al.
Publicado: (2020)

Authors’ reply to a commentary on the potential impact of COVID-19 passports to epidemiological situation
por: Stankūnas, Mindaugas, et al.
Publicado: (2023)

Reply to letter to the editor “antibody responses to second doses of COVID-19 vaccination in lung cancer patients: Comment”
por: Narita, Daisuke, et al.
Publicado: (2023)

Anti-mitochondrial M2 Antibodies and Myopathy: Author's Reply
por: Konishi, Hiroki, et al.
Publicado: (2017)

Anti-mitochondrial antibody–mediated myopathy with cardiac involvement: reply
por: Nagatomo, Yuji, et al.
Publicado: (2023)

In Reply
por: Coriat, Romain, et al.
Publicado: (2017)

Reply
por: Israelsen, Simone Bastrup, et al.
Publicado: (2022)

Plasma hemoglobin in COVID-19: authors’ reply
por: Lancman, Guido, et al.
Publicado: (2020)

In reply—The “Perfect Cytokine Storm” of COVID-19
por: Vijayvargiya, Prakhar, et al.
Publicado: (2020)

Reply to Comment on “Osteoporosis in the Age of COVID-19”
por: Girgis, C. M., et al.
Publicado: (2021)

Reply to “Pulmonary toxicity by oxygen and COVID-19”()
por: Belenguer-Muncharaz, A., et al.
Publicado: (2022)

Reply To: Response to COVID-19 by the surgical community
por: Chapman, Robert
Publicado: (2020)

Type and dose of heparin in Covid‐19: Reply
por: Thachil, Jecko, et al.
Publicado: (2020)

Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
por: Brand, Christian, et al.
Publicado: (2018)

ESCMID COVID-19 living guidelines: drug treatment and clinical management: author's reply
por: Bartoletti, Michele, et al.
Publicado: (2022)

Drug-drug interaction with oral antivirals for early treatment of COVID-19 – Authors’ reply
por: Larsen, Carsten Schade
Publicado: (2023)

Reply
por: Algarroba, Gabriela N., et al.
Publicado: (2020)

Non-aneurysmal subarachnoid haemorrhage in COVID-19—authors’ reply to Kawada T
por: Harrogate, Suzanne, et al.
Publicado: (2021)

Author's reply
por: Thomas, Sanjeev V.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_iso36k1st57nuuqjg66naiuf9r